about
Animal models of myasthenia gravis: utility and limitationsA superfluorinated molecular probe for highly sensitive in vivo(19)F-MRI.Myasthenia gravis (MG): epidemiological data and prognostic factors.Risk factors for tumor occurrence in patients with myasthenia gravis.VAV1 and BAFF, via NFκB pathway, are genetic risk factors for myasthenia gravis.An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma.Increased toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution.The thymus in myasthenia gravis: Site of "innate autoimmunity"?Development of the MG-DIS: an ICF-based disability assessment instrument for myasthenia gravis.A propensity score analysis for comparison of T-3b and VATET in myasthenia gravis.A novel infection- and inflammation-associated molecular signature in peripheral blood of myasthenia gravis patients.Increased expression of Toll-like receptors 7 and 9 in myasthenia gravis thymus characterized by active Epstein-Barr virus infection.A Novel Approach to Reinstating Tolerance in Experimental Autoimmune Myasthenia Gravis Using a Targeted Fusion Protein, mCTA1-T146.Differential targeting of immune-cells by Pixantrone in experimental myasthenia gravis.Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies.Complete stable remission and autoantibody specificity in myasthenia gravis.Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator?Validity, reliability, and sensitivity to change of the myasthenia gravis activities of daily living profile in a sample of Italian myasthenic patients.Toll-like receptors 7 and 9 in myasthenia gravis thymus: amplifiers of autoimmunity?Validation of the italian version of the 15-item Myasthenia Gravis Quality-of-Life questionnaire.Suppression of CHRN endocytosis by carbonic anhydrase CAR3 in the pathogenesis of myasthenia gravis.Plasma treatment in diseases of the neuromuscular junction.Oral administration of an immunodominant TAChR epitope modulates antigen-specific T cell responses in mice.Anti-titin and antiryanodine receptor antibodies in myasthenia gravis patients with thymoma.Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association.Validation of the Besta Neurological Institute rating scale for myasthenia gravis.Allorecognition of human neural stem cells by peripheral blood lymphocytes despite low expression of MHC molecules: role of TGF-beta in modulating proliferation.In vivo quantitative magnetization transfer imaging correlates with histology during de- and remyelination in cuprizone-treated mice.Gut microbiota and probiotics: novel immune system modulators in myasthenia gravis?Diagnostics of myasthenic syndromes: detection of anti-AChR and anti-MuSK antibodies.Identification of a gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-modifying therapies.Altered miRNA expression is associated with neuronal fate in G93A-SOD1 ependymal stem progenitor cells.Analysis of SjTREC levels in thymus from MG patients and normal children.Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis.Administration of bifidobacterium and lactobacillus strains modulates experimental myasthenia gravis and experimental encephalomyelitis in Lewis rats.Naturally occurring CD4+CD25+ regulatory T cells prevent but do not improve experimental myasthenia gravisThe Kinesin Superfamily Motor Protein KIF4 Is Associated With Immune Cell Activation in Idiopathic Inflammatory MyopathiesInnate immunity in myasthenia gravis thymus: Pathogenic effects of Toll-like receptor 4 signaling on autoimmunityA New Thiopurine S-Methyltransferase Haplotype Associated With Intolerance to AzathioprineThymoma-associated myasthenia gravis: Outcome, clinical and pathological correlations in 197 patients on a 20-year experience
P50
Q26750632-A4719F6F-FB75-470B-B8D0-5329321B886BQ30828117-A073FD8F-4F04-4B42-8CE1-DAAA02B21F68Q30883242-7AF64301-74F9-4B86-B659-16764593C510Q33423900-CA6AD07A-6AF7-4D62-B90E-16925D5FB580Q34286801-E7BCE7B5-770A-4494-886E-4A9AF245078CQ34533616-C5FAC0C6-B869-4C27-8B5B-0E1A4102F7F5Q35084929-0A249EAE-1E9A-4339-9157-F5B75BBFABD4Q37933171-22853635-F035-41BD-8ACC-C9808B5DDDCDQ38115565-7DF995F2-9C53-4877-AE9B-958304D073E1Q38737653-5699DC73-B520-4506-8252-0E4080E18682Q39624304-0E54FC70-8E94-4713-998A-14440C51A9FCQ40152324-A8528254-E291-49A2-ACF3-F6956EA37394Q41673068-A0861ACD-B310-494E-9410-A213E2B1B97AQ42712347-F3F0D48F-5A40-40B5-9FEA-607E9472DEBCQ43640120-852A222C-A660-4AD5-A17B-809B61B8156DQ44076910-B10B0C08-9172-4968-9C20-CC7C0297E3E3Q45323590-153D477B-0C21-42EE-A7E7-68F79034275BQ47303718-807EB2FC-B35B-4654-B5F0-031F4AD40150Q47549382-7A064CAB-C7E7-4AF3-BB33-D6EB09E53757Q47597263-548FE841-DE0F-4EBB-AAD8-58C3AAB0C245Q47768895-CBDE062F-23BC-426F-A3FE-357FE4B16C16Q47826068-D42B2D33-50FA-445A-B9C6-11B71EEB068CQ47826355-BCC5AEF2-EF0C-4D2B-8D74-1F73BAF383DFQ47826442-0A03E635-EB73-4AAC-821E-343F6B33D88AQ47897582-1CBB3343-B38A-4362-8D2C-15E8ABCB8046Q48007236-82300E7B-881A-45A8-B05F-6C2E05FF3725Q48092257-B136E017-FF81-44C5-953B-21CA4523C9F3Q48350506-72048704-D205-4A69-BF78-EC9DE8B20347Q50010788-CB1B1008-CC2F-4289-B3F2-2BD30BF5268CQ50067521-18E65358-FA08-41E3-8074-B4ACBA24571BQ51412669-8BAC4623-CB2D-4184-ABB2-0B8A5244D081Q53076822-DB3FE4DC-E42D-42F9-9E1E-B1543F42AF1CQ54745865-5B3C3B75-461C-4E27-A26F-6507B9613074Q55052794-8E6B2911-3BE4-4E13-B334-91DFEBA2220EQ55293326-39958881-538F-4255-A2BF-F20D4B444509Q56899334-B98EF0BD-1D23-4C2F-83ED-D84990EA1BDEQ58875758-D6E75E64-5FE0-4952-9A0C-B3D599CFFB1FQ61827977-764E4A8D-0437-41CD-9E75-0EC2F11E493CQ61827985-DD694199-2A3E-4FD8-A384-EB5DC0199A62Q61828018-73D6EF9B-4FF8-4933-8076-D43C6B2CD2B4
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Fulvio Baggi
@ast
Fulvio Baggi
@en
Fulvio Baggi
@es
Fulvio Baggi
@nl
Fulvio Baggi
@sl
type
label
Fulvio Baggi
@ast
Fulvio Baggi
@en
Fulvio Baggi
@es
Fulvio Baggi
@nl
Fulvio Baggi
@sl
prefLabel
Fulvio Baggi
@ast
Fulvio Baggi
@en
Fulvio Baggi
@es
Fulvio Baggi
@nl
Fulvio Baggi
@sl
P106
P1153
6701392715
P31
P496
0000-0002-4618-0102